PILOPINE HS
Clinical safety rating: caution
Comprehensive clinical and safety monograph for PILOPINE HS (PILOPINE HS).
Pilocarpine is a cholinergic parasympathomimetic agent that directly stimulates muscarinic receptors, particularly the M3 subtype, in ocular smooth muscle (e.g., iris sphincter and ciliary muscle), leading to miosis and accommodation spasm. Topical application reduces intraocular pressure by enhancing aqueous humor outflow through the trabecular meshwork.
| Metabolism | Primarily metabolized by plasma esterases, with hydrolysis to inactive metabolites. Minimal hepatic metabolism. |
| Excretion | Primarily renal (80-90% as unchanged drug via glomerular filtration and tubular secretion); minimal biliary/fecal (1-2%) |
| Half-life | 2-4 hours terminal in healthy adults; prolonged to 4-6 hours in elderly or those with renal impairment. Clinical context: requires multiple daily dosing (typically 4 times daily) due to short half-life. |
| Protein binding | <20% bound to plasma proteins (primarily albumin) |
| Volume of Distribution | 1-2 L/kg (widespread distribution, including ocular tissues; clinical meaning: extensive peripheral distribution, low initial plasma concentrations) |
| Bioavailability | Topical ophthalmic: approximately 0.5-1% (due to corneal barrier and nasolacrimal drainage); oral: 30-40% (subject to first-pass metabolism) |
| Onset of Action | Oral: 15-30 minutes (peak effect at 1 hour for ocular pilocarpine, but note that Pilopine HS is a topical gel for glaucoma). For topical ophthalmic gel: 10-30 minutes for intraocular pressure reduction with maximum effect at 2-4 hours. |
| Duration of Action | Topical ophthalmic gel: 8-12 hours (due to sustained-release formulation); clinical note: once-daily dosing at bedtime is recommended for nocturnal IOP control. |
1 drop of 0.1% solution in the conjunctival sac of each affected eye at bedtime.
| Dosage form | GEL |
| Renal impairment | No dose adjustment required for renal impairment. |
| Liver impairment | No dose adjustment required for hepatic impairment. |
| Pediatric use | Safety and efficacy not established in pediatric patients; use not recommended. |
| Geriatric use | No specific adjustment; use same dosing as adults, but monitor for systemic effects due to potential increased absorption. |
| 1st trimester | Consult provider |
| 2nd trimester | Consult provider |
| 3rd trimester | Consult provider |
Clinical note
Comprehensive clinical and safety monograph for PILOPINE HS (PILOPINE HS).
| Breastfeeding | Pilocarpine is excreted in human breast milk; M/P ratio not reported. The effect on the nursing infant is unknown. Caution is advised; consider risk versus benefit and monitor infant for cholinergic adverse effects (e.g., diarrhea, hypersalivation, bronchospasm). |
| Teratogenic Risk | Pilocarpine is classified as FDA Pregnancy Category C. No adequate and well-controlled studies in pregnant women. In animal studies, pilocarpine exhibited embryotoxic effects at doses 10 times the maximum recommended human dose. First trimester: Risk cannot be ruled out; use only if benefit outweighs risk. Second and third trimesters: Potential for increased uterine tone and fetal bradycardia; avoid use near term due to possible cholinergic effects on fetus. |
■ FDA Black Box Warning
None.
| Common Effects | Application site reactions burning irritation itching and redness |
| Serious Effects |
["Hypersensitivity to pilocarpine or any component of the formulation.","Any condition where miosis is undesirable (e.g., acute iritis, anterior uveitis, glaucoma secondary to iridocyclitis).","Uncontrolled asthma or chronic obstructive pulmonary disease (COPD) due to potential bronchospasm.","Narrow-angle glaucoma unless controlled by iridectomy.","Concurrent use with topical nonsteroidal anti-inflammatory drugs (NSAIDs) in patients with active corneal lesions."]
| Precautions | ["Risk of retinal detachment in patients with pre-existing retinal disease or high myopia.","Caution in patients with acute iritis or uveitis due to potential exacerbation.","May cause temporary blurred vision or night vision disturbance; advise caution when driving or operating machinery, especially in dim light.","Systemic absorption may cause increased salivation, sweating, nausea, or bradycardia; use with caution in patients with conditions exacerbated by parasympathomimetic effects (e.g., asthma, hyperthyroidism, peptic ulcer, urinary tract obstruction).","Prolonged use may lead to iris pigment epithelial cysts or synechiae."] |
Loading safety data…
| Fetal Monitoring | Monitor for maternal cholinergic toxicity (e.g., bradycardia, hypotension, bronchospasm, increased secretions). Fetal heart rate monitoring recommended during prolonged use or at term due to potential for fetal bradycardia and uterine hyperstimulation. Assess fetal growth and amniotic fluid index regularly. |
| Fertility Effects | Pilocarpine may impair fertility in males and females based on animal studies (decreased spermatogenesis, altered estrous cycle). Human data limited; consider potential reversible effects on reproductive function. |